The client was a global pharmaceutical company specializing in vaccines. They have recently developed a COVID-19 vaccine and wanted to prove its economic value. To assist them, we developed a cost-effectiveness model comparing their vaccine to those currently in use, and an economic SLR/TLR to support the model and provide information to discover a niche for their product.
In the rapidly changing landscape of COVID-19, the information identified in the economic SLR had already been dated when the SLR was finished and the report was being written. Most of the articles considered initial COVID vaccinations, while at the time, booster vaccinations were more relevant. In addition, new variants of COVID-19 were not researched in the identified articles.